In this blog, Emily Klein reflects on the importance of Rare Disease Day in bringing visibility to those affected by a rare condition and serving as a focal point for advocacy in this space.
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
In this blog, Katherine Powers, Life Sciences Senior Analyst at RSM US, and Max Stanyard, Life Sciences Senior Analyst at RSM UK, highlight the investment uncertainty in the UK-US life sciences ecosystem.
The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.
In this blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
In this guest blog, Hareklea Markides, Innovation Lead - Medicines Manufacturing at Innovate UK, reflects on the UK BioIndustry Association's (BIA) annual #bioProcessUK conference.
TechBio’s potential to both transform our sector and provide precision diagnosis and care to patients is well recognised, and TechBio Boost is playing a vital role in scaling companies in this space.
In this blog, Abby Clark, Manufacturing Programme Manager at BIA, highlights some of the key achievements of BIA and ABPI’s Medicines Manufacturing Industry Partnership (MMIP).
In this guest blog, BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, shares expert insight into the UK’s evolving R&D tax relief landscape for life sciences companies.
A bumper update today as we highlight the critical importance of building UK capability and innovation leadership as geopolitics continues to provide uncertainty.
What an incredible night! Last Thursday, we welcomed a record 780 of you to the Roundhouse for the 2026 BIA Gala Dinner. It was a powerful reminder of the strength, resilience and sheer brilliance of our community.
In this blog, Saqib Lal, Head of Content at BIA, reflects on a stellar Gala Dinner. He describes it as a moment to pause and recognise the extraordinary people who make the UK life sciences sector a global powerhouse. This year, as a record 780 guests gathered at the iconic Roundhouse for an evening that demonstrated renewed ambition and positivity.
In this blog, Emily Klein, Senior Policy and Public Affairs Executive at BIA, explores the hidden, wide-ranging impacts and costs of rare diseases to society and the wider economy in the UK.
As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series.
Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.
With a number of unprecedented leaks, speculation and media briefings indicating potential wide ranging and significant tax rises, in the end the 2025 Autumn Budget seemed to be one of restraint and headline rates remained untouched.
